Wedbush Securities Sees Dose Escalation Trials Continue Without Toxicity Signals For Endocyte
March 03, 2015 at 08:50 AM EST
In a report published Tuesday, Wedbush Securities analyst David M. Nierengarten reiterated an Outperform rating and $12.00 price target ...
